Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health technologies, has achieved two significant regulatory milestones with approvals for its Verdye (indocyanine green) injectable imaging agent in the Philippines and its IC-Flow Imaging System V2 in Malaysia.
The dual approvals mark a pivotal step in UltraGreen.ai’s regional expansion strategy across Southeast Asia, a market characterized by rising surgical volumes, growing healthcare infrastructure investment, and increasing demand for precision-guided surgical technologies.
Advancing Fluorescence-Guided Surgery Across Multiple Specialties
Fluorescence-guided surgery using indocyanine green (ICG) has emerged as a valuable clinical tool across oncology, colorectal, reconstructive, and vascular procedures. The regulatory clearance of UltraGreen.ai’s solutions enables broader access to real-time visualization technologies that support intra-operative decision-making and surgical accuracy.
- The IC-Flow Imaging System V2, now approved in Malaysia, enables fluorescence imaging integration within routine clinical workflows.
- The approval of Verdye in the Philippines provides clinicians access to a globally established ICG imaging agent supported by extensive clinical experience across international markets.
Together, the approvals create a foundation for scaled adoption of fluorescence-guided techniques in both countries.
From Products to Platforms: Integrating AI into Surgical Care
Beyond imaging agents and hardware, UltraGreen.ai is pursuing a platform-driven approach to precision surgery. The company is developing an AI-powered data platform designed to support surgical standardization, analytics, and decision-support across multiple procedures and specialties.
This strategy reflects a broader industry trend toward data-enabled surgical ecosystems, where imaging, pharmaceuticals, and AI converge to enhance clinical outcomes and operational efficiency.
Building Regional Capability Through Education and Partnerships
With regulatory approvals in place, UltraGreen.ai and its local partners plan to expand surgeon education, training, and clinical support programs across both markets. The company’s regional approach emphasizes not only market access but also capability building to support consistent and high-quality adoption of fluorescence-guided techniques.
Southeast Asia continues to experience rapid growth in surgical demand, particularly in oncology-related procedures, increasing the need for scalable, easy-to-adopt visualization technologies that do not add infrastructure complexity.
Strategic Outlook
The approvals in the Philippines and Malaysia reinforce UltraGreen.ai’s long-term commitment to Southeast Asia and position the company to participate in the region’s transition toward precision, image-guided, and AI-supported surgery.
As regulatory momentum, clinical adoption, and digital integration continue into 2026, UltraGreen.ai’s expanding footprint highlights the growing role of fluorescence imaging and AI-enabled platforms in shaping the future of surgical care across emerging healthcare markets.
By